Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma

Multiple myeloma has a continued need for more effective and durable therapies. B cell maturation antigen (BCMA), a plasma cell surface antigen and member of the tumor necrosis factor (TNF) receptor superfamily, is an attractive target for immunotherapy of multiple myeloma due to its high prevalence...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Bu, De-Xiu, Singh, Reshma, Choi, Eugene E., Ruella, Marco, Nunez-Cruz, Selene, Mansfield, Keith G., Bennett, Paul, Barton, Nathanial, Wu, Qilong, Zhang, Jiquan, Wang, Yongqiang, Wei, Lai, Cogan, Shawn, Ezell, Tucker, Joshi, Shree, Latimer, Kellie J., Granda, Brian, Tschantz, William R., Young, Regina M., Huet, Heather A., Richardson, Celeste J., Milone, Michael C.
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5995247/
https://ncbi.nlm.nih.gov/pubmed/29899820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25359
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares